Deerfield Management TNDM Position
ActiveDeerfield Management increased their position in TANDEM DIABETES CARE INC (TNDM) in Q4 2025, holding $573K worth of shares across 26,090 shares.
The position was first reported in Q3 2025 and has been tracked across 2 quarterly 13F filings.
1 other tracked fund also holds TNDM.
Short interest stands at 21.3% of float with 3.5 days to cover, indicating significant bearish positioning against Deerfield's long thesis.
About TANDEM DIABETES CARE INC
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Full company profile →Short Interest
21.3%
3.5 days to cover
Deerfield Management TNDM Position History
Frequently Asked Questions
Does Deerfield Management own TNDM?
Yes. As of Q4 2025, Deerfield Management holds 26,090 shares of TANDEM DIABETES CARE INC (TNDM) valued at $573K. This data comes from their SEC 13F filing.
How many hedge funds own TNDM?
2 specialist biotech hedge funds currently hold TNDM, including Driehaus Capital. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Deerfield Management first buy TNDM?
Deerfield Management's position in TNDM was first reported in Q3 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Deerfield Management's TNDM position increasing or decreasing?
Deerfield Management increased their TNDM position in the most recent quarter, adding 13,895 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
TNDMCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Deerfield ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →